# US 9,434,700 B2 · Inhibitors of the fibroblast growth factor receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,434,700 B2
- Document ID: US9434700B2
- Status: Granted
- Kind: B2
- Application number: 14/521,909
- Filed: 2014-10-23
- Published: 2015-04-30
- Granted: 2016-09-06
- Earliest claimed: 2013-10-25
- Applicants: Neil Bifulco, Jr.; Lucian V. DiPietro; Brian L. Hodous; Chandrasekhar V. Miduturu
- Inventors: Neil Bifulco, Jr.; Lucian V. DiPietro; Brian L. Hodous; Chandrasekhar V. Miduturu
- Web page: https://patentgrep.com/patent/US9434700B2

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/06: Antihyperlipidemics
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 235/30: Nitrogen atoms not forming part of a nitro radical
- C07D 239/84: Nitrogen atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 403/14: containing three or more hetero rings
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 409/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 475/00: Heterocyclic compounds containing pteridine ring systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are inhibitors of FGFR-4, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.

## Claims

### Claim 1

A compound or pharmaceutically acceptable salt thereof, wherein the compound is:

### Claim 2 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 3

A compound or pharmaceutically acceptable salt thereof, wherein the compound is:

### Claim 4 (depends on 3)

A pharmaceutical composition comprising the compound of claim 3 or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.